Robert L Findling1, Ronald P Landbloom2, Mary Mackle2, Wendi Pallozzi3, Sabine Braat4, Carla Hundt5, Marianne Z Wamboldt6, Maju Mathews5. 1. 1 The Johns Hopkins University/Kennedy Krieger Institute , Baltimore, Maryland. 2. 2 Merck , Whitehouse Station, New Jersey. 3. 3 Merck , Whitehouse Station, New Jersey. 4. 4 Merck , Oss, The Netherlands . 5. 5 Forest Research Institute , an affiliate of Actavis Inc, Jersey City, New Jersey. 6. 6 University of Colorado/Children's Hospital Colorado , Aurora, Colorado.
Abstract
OBJECTIVE: The purpose of this study was to evaluate the safety and efficacy of asenapine in adolescents with schizophrenia. METHODS: In an 8 week, randomized, double-blind placebo-controlled trial, subjects (12-17 years of age) meeting Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria for schizophrenia were randomized 1:1:1 to placebo, asenapine 2.5 mg b.i.d., or asenapine 5 mg b.i.d. Subjects who completed the 8 week acute study could participate in a 26 week flexible-dose asenapine-only open-label extension (OLE). RESULTS: A similar percentage of subjects completed treatment on day 56 (2.5 mg b.i.d. (n=98): 83%; 5 mg b.i.d. [n=106]: 79%; placebo [n=102]: 79%). In the mixed model for repeated measures analysis of the primary end-point (with Hochberg correction for multiplicity), least squares (LS) mean differences between asenapine and placebo on the Positive and Negative Syndrome Scale (PANSS) total score at day 56 were not significant (-4.8 for 2.5 mg b.i.d., p=0.070; -5.6 for 5 mg b.i.d., p=0.064). Significant improvement in the Clinical Global Impressions-Severity score was observed in the 5 mg b.i.d. group versus placebo on day 56 (LS mean -0.3, p=0.024). In the acute phase, ≥7% weight gain and the composite event of somnolence, sedation, and hypersomnia were more common in both asenapine groups than in the placebo group. Akathisia, fasting glucose elevation, and extrapyramidal syndrome were more common in the 5 mg b.i.d. group than in the placebo group. There were no unexpected adverse events in the OLE, and PANSS total scores decreased by -16.1 points in the group previously treated with placebo (n=62) and by -11.2 points in the continuous asenapine group (n=131) from OLE baseline to week 26. CONCLUSIONS: Although improvements in PANSS total score at day 56 of the acute phase were numerically greater for both asenapine 2.5 and 5 mg b.i.d. than for placebo and were maintained in the OLE, the primary end-point did not achieve statistical significance in the acute phase. No new or unexpected safety concerns were detected during the acute phase or after an additional 26 weeks of asenapine treatment in the adolescent population with schizophrenia. CLINICAL TRIALS REGISTRY: NCT01190254 and NCT1190267 at ClinicalTrials.gov.
RCT Entities:
OBJECTIVE: The purpose of this study was to evaluate the safety and efficacy of asenapine in adolescents with schizophrenia. METHODS: In an 8 week, randomized, double-blind placebo-controlled trial, subjects (12-17 years of age) meeting Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria for schizophrenia were randomized 1:1:1 to placebo, asenapine 2.5 mg b.i.d., or asenapine 5 mg b.i.d. Subjects who completed the 8 week acute study could participate in a 26 week flexible-dose asenapine-only open-label extension (OLE). RESULTS: A similar percentage of subjects completed treatment on day 56 (2.5 mg b.i.d. (n=98): 83%; 5 mg b.i.d. [n=106]: 79%; placebo [n=102]: 79%). In the mixed model for repeated measures analysis of the primary end-point (with Hochberg correction for multiplicity), least squares (LS) mean differences between asenapine and placebo on the Positive and Negative Syndrome Scale (PANSS) total score at day 56 were not significant (-4.8 for 2.5 mg b.i.d., p=0.070; -5.6 for 5 mg b.i.d., p=0.064). Significant improvement in the Clinical Global Impressions-Severity score was observed in the 5 mg b.i.d. group versus placebo on day 56 (LS mean -0.3, p=0.024). In the acute phase, ≥7% weight gain and the composite event of somnolence, sedation, and hypersomnia were more common in both asenapine groups than in the placebo group. Akathisia, fasting glucose elevation, and extrapyramidal syndrome were more common in the 5 mg b.i.d. group than in the placebo group. There were no unexpected adverse events in the OLE, and PANSS total scores decreased by -16.1 points in the group previously treated with placebo (n=62) and by -11.2 points in the continuous asenapine group (n=131) from OLE baseline to week 26. CONCLUSIONS: Although improvements in PANSS total score at day 56 of the acute phase were numerically greater for both asenapine 2.5 and 5 mg b.i.d. than for placebo and were maintained in the OLE, the primary end-point did not achieve statistical significance in the acute phase. No new or unexpected safety concerns were detected during the acute phase or after an additional 26 weeks of asenapine treatment in the adolescent population with schizophrenia. CLINICAL TRIALS REGISTRY: NCT01190254 and NCT1190267 at ClinicalTrials.gov.
Authors: John M Kane; Mary Mackle; Linda Snow-Adami; Jun Zhao; Armin Szegedi; John Panagides Journal: J Clin Psychiatry Date: 2011-02-22 Impact factor: 4.384
Authors: Robert L Findling; Idil Cavuş; Elizabeth Pappadopulos; Douglas G Vanderburg; Jeffrey H Schwartz; Balarama K Gundapaneni; Melissa P DelBello Journal: J Child Adolesc Psychopharmacol Date: 2013-10-10 Impact factor: 2.576
Authors: Jean A Frazier; Anthony J Giuliano; Jacqueline L Johnson; Lauren Yakutis; Eric A Youngstrom; David Breiger; Linmarie Sikich; Robert L Findling; Jon McClellan; Robert M Hamer; Benedetto Vitiello; Jeffrey A Lieberman; Stephen R Hooper Journal: J Am Acad Child Adolesc Psychiatry Date: 2012-03-13 Impact factor: 8.829
Authors: Jean A Frazier; Jon McCLELLAN; Robert L Findling; Benedetto Vitiello; Robert Anderson; Benjamin Zablotsky; Emily Williams; Nora K McNAMARA; Joseph A Jackson; Louise Ritz; Stefanie A Hlastala; Leslie Pierson; Jennifer A Varley; Madeline Puglia; Ann E Maloney; Denisse Ambler; Tyehimba Hunt-Harrison; Robert M Hamer; Nancy Noyes; Jeffrey A Lieberman; Linmarie Sikich Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-08 Impact factor: 8.829
Authors: Marco Solmi; Michele Fornaro; Edoardo G Ostinelli; Caroline Zangani; Giovanni Croatto; Francesco Monaco; Damir Krinitski; Paolo Fusar-Poli; Christoph U Correll Journal: World Psychiatry Date: 2020-06 Impact factor: 49.548
Authors: Peter Dogterom; Robert Riesenberg; Rik de Greef; Justin Dennie; Martin Johnson; Venkatesh Pilla Reddy; André Mm Miltenburg; Robert L Findling; Abhijeet Jakate; Timothy J Carrothers; Matthew D Troyer Journal: Drug Des Devel Ther Date: 2018-08-30 Impact factor: 4.162